Literature DB >> 35419546

SGLT2 Inhibitors: Physiology and Pharmacology.

Ernest M Wright1.   

Abstract

SGLTs are sodium glucose transporters found on the luminal membrane of the proximal tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each day. The natural glucoside phlorizin completely blocks glucose reabsorption. Oral SGLT2 inhibitors are rapidly absorbed into the blood stream, where theyremain in the circulation for hours. On glomerular filtration, they bind specifically to SGLT2 in the luminal membrane of the early proximal tubule to reduce glucose reabsorption by 50%-60%. Because of glucose excretion, these drugs lower plasma glucose and glycosylated hemoglobin levels in patients with type 2 diabetes mellitus. The drugs also protect against heart and renal failure. The aim of this review is to summarize what is known about the physiology of renal SGLTs and the pharmacology of SGLT drugs.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  SGLT; SGLT2; basic science; diabetes; glucose; heart failure; inhibitors; renal physiology; sodium glucose transporters

Mesh:

Substances:

Year:  2021        PMID: 35419546      PMCID: PMC8986039          DOI: 10.34067/KID.0002772021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  59 in total

1.  Functional asymmetry of the human Na+/glucose transporter (hSGLT1) in bacterial membrane vesicles.

Authors:  Matthias Quick; Jelena Tomasevic; Ernest M Wright
Journal:  Biochemistry       Date:  2003-08-05       Impact factor: 3.162

2.  Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.

Authors:  Ana M Pajor; Kathleen M Randolph; Sandy A Kerner; Chari D Smith
Journal:  J Pharmacol Exp Ther       Date:  2007-12-06       Impact factor: 4.030

3.  Expression cloning and cDNA sequencing of the Na+/glucose co-transporter.

Authors:  M A Hediger; M J Coady; T S Ikeda; E M Wright
Journal:  Nature       Date:  1987 Nov 26-Dec 2       Impact factor: 49.962

4.  Kinetics of the reverse mode of the Na+/glucose cotransporter.

Authors:  S Eskandari; E M Wright; D D F Loo
Journal:  J Membr Biol       Date:  2005-03       Impact factor: 1.843

5.  Common mechanisms of inhibition for the Na+/glucose (hSGLT1) and Na+/Cl-/GABA (hGAT1) cotransporters.

Authors:  B A Hirayama; A Díez-Sampedro; E M Wright
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport.

Authors:  Salem Faham; Akira Watanabe; Gabriel Mercado Besserer; Duilio Cascio; Alexandre Specht; Bruce A Hirayama; Ernest M Wright; Jeff Abramson
Journal:  Science       Date:  2008-07-03       Impact factor: 47.728

7.  Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting.

Authors:  J Calado; J Loeffler; O Sakallioglu; F Gok; K Lhotta; J Barata; J Rueff
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

8.  Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.

Authors:  Brian Zambrowicz; Ike Ogbaa; Kenny Frazier; Phillip Banks; Anne Turnage; Joel Freiman; Kristi A Boehm; Dennis Ruff; David Powell; Arthur Sands
Journal:  Clin Ther       Date:  2013-07-31       Impact factor: 3.393

9.  Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.

Authors:  Hiddo J L Heerspink; Avraham Karasik; Marcus Thuresson; Cheli Melzer-Cohen; Gabriel Chodick; Kamlesh Khunti; John P H Wilding; Luis Alberto Garcia Rodriguez; Lucia Cea-Soriano; Shun Kohsaka; Antonio Nicolucci; Giuseppe Lucisano; Fang-Ju Lin; Chih-Yuan Wang; Eric Wittbrodt; Peter Fenici; Mikhail Kosiborod
Journal:  Lancet Diabetes Endocrinol       Date:  2020-01       Impact factor: 32.069

10.  Active site voltage clamp fluorometry of the sodium glucose cotransporter hSGLT1.

Authors:  Edurne Gorraitz; Bruce A Hirayama; Aviv Paz; Ernest M Wright; Donald D F Loo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

View more
  3 in total

Review 1.  Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy.

Authors:  Constantin Munteanu; Mariana Rotariu; Marius-Alexandru Turnea; Aurelian Anghelescu; Irina Albadi; Gabriela Dogaru; Sînziana Calina Silișteanu; Elena Valentina Ionescu; Florentina Carmen Firan; Anca Mirela Ionescu; Carmen Oprea; Gelu Onose
Journal:  Curr Issues Mol Biol       Date:  2022-07-28       Impact factor: 2.976

2.  Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis.

Authors:  Zofia Wicik; Anna Nowak; Joanna Jarosz-Popek; Marta Wolska; Ceren Eyileten; Jolanta M Siller-Matula; Dirk von Lewinski; Harald Sourij; Krzysztof J Filipiak; Marek Postuła
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

Review 3.  Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials.

Authors:  Lucia Scisciola; Vittoria Cataldo; Fatemeh Taktaz; Rosaria Anna Fontanella; Ada Pesapane; Puja Ghosh; Martina Franzese; Armando Puocci; Antonella De Angelis; Liberata Sportiello; Raffaele Marfella; Michelangela Barbieri
Journal:  Front Cardiovasc Med       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.